Genmab A/S reported a 60% increase in revenue to DKK 1.8 billion (€244.27 million) in 2016, largely due to higher than expected royalties on sales of Darzalex (daratumumab), a treatment for multiple myeloma, as well as milestone payments from its licensee Janssen Biotech Inc.
